Celonic Group
Rita Bhattacherjee is an experienced professional in the biopharmaceutical industry, currently serving as a Senior Process Specialist USP at Celonic Group since August 2024, where responsibilities include process and tech-transfer, validation, production planning, and risk assessment. Prior to this role, Rita worked at ProBioGen AG as an Engineer in Fill and Finish, focusing on qualification and documentation in a GMP environment, and at IDT Biologika as a Process Technologist, overseeing media fill processes and handling deviations. Rita’s background also includes significant academic and research experience, such as a Master’s thesis at DBFZ on bioreactor engineering and various internships related to biotechnology and bioremediation. Rita holds a Master of Science in Pharmaceutical and Industrial Biotechnology from The Martin Luther University of Halle-Wittenberg and a Bachelor of Technology in Biotechnology from Heritage Institute of Technology.
This person is not in any teams
This person is not in any offices
Celonic Group
Celonic is a global CDMO (Contract Development & Manufacturing Organization) for innovative biopharmaceuticals and is part of the private and independent family-owned company J.RETTENMAIER & Söhne (JRS Group), with sites in Basel, Switzerland (Headquarters) and Heidelberg, Germany. Celonic provides comprehensive development and manufacturing services for biotherapeutics, including cell line development, USP and DSP development, GMP and non-GMP manufacturing of biopharmaceutical drug substances. Celonic services covered: 2 INDUSTRY LEADING CELL EXPRESSION PLATFORMS: CHOvolution™: - Powered by Celonic's proprietary SEFEX™ technology - Cell line based on CHO-K1 (non-genetically modified CHO) - Cell line adapted to serum-free EMA and FDA compliant media - Simplified licensing model (no royalties from sales) - High productivity (>7 g/l for mABs) GEX®: - Human cells for fully-human glycosylation - Optimized for complex and sophisticated biopharmaceutical products - Stable product quality over full run-time for R&D and/or GMP - High productivity (up to 22g/l bioreactor volume for mAbs ) PROCESS DEVELOPMENT: - State-of-art USP and DSP development - Cutting-edge, in-house, and high throughput bioanalytics - Robust and scalable BIOMANUFACTURING CAPACITIES: - Two facilities (Germany and Basel) - Up to 2,000 L capacity batches in GMP and R&D setup - In-house analytics - Swissmedic GMP certified - 20 years of optimizing perfusion technique with >100 GMP batches NEW BIOLOGICAL ENTITIES : Celonic offers comprehensive approaches to enable clients to achieve commercial success, with a proven track record of developing breakthrough biologics and delivering GMP batches of ex. mABs, Growth Hormones, Fusion Proteins, and Blood Factors. BIOSIMILARS : Celonic offers ready-to-go Biosimilars (cell lines and cell pools—comprehensive analytics methods, comparability data, and development process) shaped on co-development and co-investment of next wave Biosimilars.